Literature DB >> 15744337

High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma.

S T P Deloose1, L A Smit, F T Pals, M-J Kersten, C J M van Noesel, S T Pals.   

Abstract

Kaposi sarcoma-associated herpesvirus (KSHV) is known to be associated with two distinct lymphoproliferative disorders: primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD)/MCD-associated plasmablastic lymphoma. We here report a high incidence of KSHV infection in solid HIV-associated immunoblastic/plasmablastic non-Hodgkin's lymphomas (NHLs), in patients lacking effusions and without evidence of (prior) MCD. Within a cohort of 99 HIV-related NHLs, 10 cases were found to be KSHV positive on the basis of immunostaining for KSHV LNA-1 as well as KSHV-specific polymerase chain reaction. All but one of the tumors coexpressed Epstein-Barr virus. Interestingly, all KSHV-positive cases belonged to a distinctive subgroup of 26 diffuse large B-cell lymphomas characterized by the expression of CD138 (syndecan-1) and plasmablastic/immunoblastic morphology. These KSHV-positive lymphomas were preceded by Kaposi sarcoma in 60% of the patients and involved the gastrointestinal tract in 80%. Our results indicate that KSHV infection is not restricted to PEL and MCD; it is also common (38%) in HIV-related solid immunoblastic/plasmablastic lymphomas.

Entities:  

Mesh:

Year:  2005        PMID: 15744337     DOI: 10.1038/sj.leu.2403709

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  32 in total

Review 1.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

2.  Human herpesvirus-encoded kinase induces B cell lymphomas in vivo.

Authors:  Penny M Anders; Nathan D Montgomery; Stephanie A Montgomery; Aadra P Bhatt; Dirk P Dittmer; Blossom Damania
Journal:  J Clin Invest       Date:  2018-05-07       Impact factor: 14.808

Review 3.  Castleman's disease: systematic analysis of 416 patients from the literature.

Authors:  Nadia Talat; Klaus-Martin Schulte
Journal:  Oncologist       Date:  2011-07-17

Review 4.  Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man: A Case Report and Review of the Literature.

Authors:  William R Foster; Alina Bischin; Russell Dorer; David M Aboulafia
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-04-01

5.  Understanding the role of miRNA in regulating NF-κB in blood cancer.

Authors:  Stuart A Rushworth; Megan Y Murray; Lawrence N Barrera; Sally-Anne Heasman; Lyubov Zaitseva; David J Macewan
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

Review 6.  Diffuse large B-cell lymphomas with plasmablastic differentiation.

Authors:  Julie Teruya-Feldstein
Journal:  Curr Oncol Rep       Date:  2005-09       Impact factor: 5.075

Review 7.  Linking KSHV to human cancer.

Authors:  Emily L Wong; Blossom Damania
Journal:  Curr Oncol Rep       Date:  2005-09       Impact factor: 5.075

Review 8.  Plasmablastic lymphoma of the small intestine: case report and literature review.

Authors:  Hong-Wei Wang; Wen Yang; Jun-Zhong Sun; Jiang-Yang Lu; Min Li; Lin Sun
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

9.  HHV-8-positive and EBV-positive intravascular lymphoma: an unusual presentation of extracavitary primary effusion lymphoma.

Authors:  Genevieve M Crane; Richard F Ambinder; Courtney M Shirley; Elliot K Fishman; Yvette L Kasamon; Janis M Taube; Michael J Borowitz; Amy S Duffield
Journal:  Am J Surg Pathol       Date:  2014-03       Impact factor: 6.394

10.  The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma.

Authors:  Farnaz D Fakhari; Joseph H Jeong; Yogita Kanan; Dirk P Dittmer
Journal:  J Clin Invest       Date:  2006-02-23       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.